We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current APLS market cap is 2.25B. The company's latest EPS is USD -1.5744 and P/E is -11.36.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 172.33M | 199.68M | 196.83M | 212.53M | 166.8M |
| Operating Income | -62.09M | -29.44M | -47.28M | -26.16M | -83.33M |
| Net Income | -66.42M | -37.66M | -57.45M | -36.35M | -92.23M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 250.65M | 66.56M | 75.42M | 396.59M | 781.37M |
| Operating Income | -213.73M | -536.28M | -594.61M | -517.12M | -164.98M |
| Net Income | -344.87M | -746.35M | -652.17M | -525.63M | -197.88M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 831.93M | 904.48M | 901.87M | 885.05M | 807.29M |
| Total Liabilities | 565.25M | 640.16M | 664.75M | 656.51M | 643.07M |
| Total Equity | 266.68M | 264.33M | 237.12M | 228.54M | 164.22M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 960.57M | 881.77M | 760.22M | 788.73M | 885.05M |
| Total Liabilities | 756.01M | 683.1M | 590.35M | 594.21M | 656.51M |
| Total Equity | 204.56M | 198.66M | 169.87M | 194.52M | 228.54M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -132.98M | -141.32M | -107.23M | -87.87M | -53.41M |
| Investing | -293k | -383k | -383k | -403k | -8k |
| Financing | 108.21M | 150.7M | 153.24M | 149.24M | 274k |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -160.49M | -563.13M | -513.75M | -594.74M | -87.87M |
| Investing | -316.99M | 247.62M | 59.89M | -674k | -403k |
| Financing | 692.18M | 392.24M | 365.66M | 394.5M | 149.24M |
| Market Cap | 2.25B |
| Price to Earnings Ratio | -11.36 |
| Price to Sales Ratio | 2.88 |
| Price to Cash Ratio | 5.47 |
| Price to Book Ratio | 9.84 |
| Dividend Yield | - |
| Shares Outstanding | 125.68M |
| Average Volume (1 week) | 1.79M |
| Average Volume (1 Month) | 1.86M |
| 52 Week Change | -51.15% |
| 52 Week High | 42.47 |
| 52 Week Low | 16.10 |
| Spread (Intraday) | 0.06 (0.34%) |
| Company Name | Apellis Pharmaceuticals Inc |
| Address |
108 lakeland ave dover, delaware 19901 |
| Website | https://www.apellis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
